Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 13/20 | 0.57 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847249 | 0.90 | PDE7A (0.57) | PDE7APDE7BPDE4BPDE4DPOLB | |
| SCHEMBL10652731 | 0.83 | ALDH1A1 (0.55) | PDE7APDE7BPDE4BPDE4DHPGD | |
| SCHEMBL282648 | 0.81 | TSHR (0.56) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL11815832 | 0.81 | VCAM1 (0.42) | PDE7APDE7BPDE4BPDE4DHPGD | |
| SCHEMBL8669659 | 0.81 | PDE7A (0.61) | PDE7APDE7BPDE4BPDE4DHPGD | |
| SCHEMBL6516022 | 0.80 | PDE7A (0.65) | PDE7APDE7BPDE4BPDE4DPOLB | |
| SCHEMBL1026140 | 0.80 | TXNRD1 (0.42) | PDE7APDE7BPDE4BPDE4DMEN1 | |
| SCHEMBL11432656 | 0.80 | ALDH1A1 (0.54) | PDE7APDE7BPDE4BPDE4DPOLB | |
| SCHEMBL6558543 | 0.80 | PDE7A (0.54) | PDE7APDE7BPDE4BPDE4DMAPK1 | |
| SCHEMBL11603010 | 0.79 | PDE7A (0.63) | PDE7APDE7BPDE4BPDE4DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976725-B1 | Process for the continuous preparation of amino-halogenophenyl alkyl thioethers | BAYER CHEMICALS AG (DE) | 2004-03-03 | — | — | EP | claimed |
| US-6077974-A | Process for the continuous preparation of amino-halo-genophenyl alkyl thioethers | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-20 | — | — | US | claimed |
| EP-0976725-A2 | Process for the continuous preparation of amino-halogenophenyl alkyl thioethers | Bayer Aktiengesellschaft (DE) | 2000-02-02 | — | — | EP | claimed |
| US-5808164-A | Process for producing aromatic sulfides | PHILLIPE PETROLEUM COMPANY (US) | 1998-09-15 | — | — | US | claimed |
| US-5618981-A | Process for producing aromatic sulfides | PHILLIPS PETROLEUM COMPANY (US) | 1997-04-08 | — | — | US | claimed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| EP-0976725-B1 | Process for the continuous preparation of amino-halogenophenyl alkyl thioethers | BAYER CHEMICALS AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6077974-A | Process for the continuous preparation of amino-halo-genophenyl alkyl thioethers | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-20 | — | — | US | disclosed |
| EP-0976725-A2 | Process for the continuous preparation of amino-halogenophenyl alkyl thioethers | Bayer Aktiengesellschaft (DE) | 2000-02-02 | — | — | EP | disclosed |
| US-5808164-A | Process for producing aromatic sulfides | PHILLIPE PETROLEUM COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5618981-A | Process for producing aromatic sulfides | PHILLIPS PETROLEUM COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | PDE7A 3077/4885PDE7B 3597/4885PDE4B 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.